Publications

Title	Details
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an an active new therapeutic strategy in lymphoma models. Haematologica 2020 Volume 205(11):2584-2591	View here
19 Jan 2021	View here
06 Jan 2021	View here

2020

Date	Title	Details
14 Oct 2020	Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic	View here
09 Jan 2020	Oxford BioTherapeutics Initiates Dose-Escalation Portion of U.S. Phase I Clinical Trial for OBT076 in Patients with Advanced Solid Tumors ​	View here

2019

Date	Title	Details
25 Jun 2019	Oxford BioTherapeutics Announces Receipt of a Milestone Payment as Boehringer Ingelheim Advances an Oncology Drug Candidate	View here

2018

Date	Title	Details
21 Dec 2018	Oxford BioTherapeutics Receives US FDA IND Clearance for OBT076: An Experimental First in Class ADC Medicine for High Risk Her2 Negative Breast Cancer, Gastric, Lung, Bladder and Ovarian Cancer Patients - US Phase I Clinical Trial to be Initiated	View here
11 Dec 2018	Oxford BioTherapeutics Expands Strategic Collaboration with  WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million	View here
01 Mar 2018	​Oxford BioTherapeutics Appoints Chief Medical Officer, ​Abderrahim Fandi	View here

2017

Date	Title	Details
13 Jun 2017	​Oxford BioTherapeutics Appoints Senior Clinical Biotech Executive as Non-Executive Director	View here
09 Feb 2017	Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans​​​​​	View here
26 Jan 2017	Oxford Finance Provides $10 Million Senior Debt Facility to Oxford BioTherapeutics​​	View here

2016

Date	Title	Details
18 Apr 2016	Boehringer Ingelheim Exercises Option on Second Oncology Target using Oxford BioTherapeutics’ OGAP® System​	View here
04 Apr 2016	Oxford BioTherapeutics Licenses Nerviano Medical Sciences’ Drug-Linker Technology to Develop Novel Antibody Drug Conjugates	View here

Media

Immunotherapies Expose and Exploit Cancer’s Varied Weaknesses
March 18 2021: “If we could understand why some people reengage their immune system after receiving chemotherapy, while others don’t, we could think about how to combine various therapeutic modalities and in what sequence”, says Christian Rohlff, PhD, CEO of Oxford BioTherapeutics. Read more here about how OBT uses proprietary immuno-oncology technology and antibody-drug conjugates to develop novel therapeutics that can reengage the immune system to destroy cancer cells.